Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Publication/Presentation Date
3-1-2017
Abstract
AIMS: Metaplastic breast carcinoma (MBC) is a rare subtype of breast carcinoma less responsive to conventional chemotherapy than ductal carcinoma. In molecular terms, MBCs usually cluster with triple-negative breast cancers (TNBCs), but have a worse prognosis than TNBCs. Studies investigating MBCs for specific biomarkers of therapy response are rare and limited by the methodological approaches. The aim of the present study was to characterise MBCs on a molecular level and test programmed death-ligand 1 (PD-L1) biomarker expression in MBCs for future therapeutic interventions.
METHODS: We profiled 297 samples (MBC (n=75), TNBC (n=106), human epidermal growth factor receptor 2 (HER2)-positive breast cancers (n=32) and hormone-positive breast cancers (n=84)) by next-generation sequencing. Immunohistochemistry for PD-L1 and programmed cell death 1 (PD-1) expression was performed using automated procedures.
RESULTS: The most commonly mutated genes in MBCs included
CONCLUSIONS: Comprehensive profiling of a large cohort of this rare subtype of breast carcinoma highlighted the predominance of
Volume
70
Issue
3
First Page
255
Last Page
259
ISSN
1472-4146
Published In/Presented At
Joneja, U., Vranic, S., Swensen, J., Feldman, R., Chen, W., Kimbrough, J., Xiao, N., Reddy, S., Palazzo, J., & Gatalica, Z. (2017). Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. Journal of clinical pathology, 70(3), 255–259. https://doi.org/10.1136/jclinpath-2016-203874
Disciplines
Medicine and Health Sciences
PubMedID
27531819
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article